NCT07249606Not yet recruiting
Momelotinib Effectiveness in Myelofibrosis
Real-world Observation of Momelotinib Effectiveness in Myelofibrosis (ROME)
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 93 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 2 Jan 2026
- Primary completion date
- 2 Jan 2028
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT07249606
What you commit to
- Study type: Observational
- Planned participants: 93
- From 2 Jan 2026 to the primary completion date, 2 Jan 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of MPN, unclassifiable, myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.
- Patients JAK inhibitors-exposed for other diseases apart from MF.
Lab values
- Patients with platelets \<20 x10(9)/L at baseline of MMB treatment.
Other
- Accelerated/blast phase of MF.
Who the study is looking for
- Patients aged 18 years or older.
- Patients diagnosed with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis start treatment with MMB according to clinical practice from AIFA authorization.
- Patients with palpable splenomegaly at baseline of momelotinib treatment.
- Informed consent signed, if applicable.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.